Enhertu recommended for EU approval in HER2-low BC
19 December 2022 07:20 GMT Enhertu recommended for approval in the EU by CHMP for patients with HER2-low metastatic breast cancer AstraZeneca and Daiichi Sankyo's Enhertu is the first HER2-directed therapy to demonstrate a significant survival benefit vs. chemotherapy in this patient population AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior